Remember The Basics: Dosing, Placebo Issues Recur In FDA Reviews
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fundamental trial design issues, from the selection of doses to the use of placebo controls, recur as problems in FDA reviews of new drugs. Post-market studies can remedy missing data, but at a cost.